The use of live attenuated influenza vaccine ts-1(E) in man.
Identifieur interne : 000647 ( PubMed/Corpus ); précédent : 000646; suivant : 000648The use of live attenuated influenza vaccine ts-1(E) in man.
Auteurs : J M GwaltneySource :
- Developments in biological standardization [ 0301-5149 ] ; 1976.
English descriptors
- KwdEn :
- Administration, Intranasal, Adult, Antibodies, Viral (analysis), Child, Clinical Trials as Topic, Female, Hemagglutination Inhibition Tests, Humans, Influenza A virus (immunology), Influenza Vaccines (administration & dosage), Influenza Vaccines (adverse effects), Influenza Vaccines (therapeutic use), Influenza, Human (prevention & control), Male, Neuraminidase (immunology), Vaccines, Attenuated (administration & dosage), Vaccines, Attenuated (adverse effects).
- MESH :
- chemical , administration & dosage : Influenza Vaccines, Vaccines, Attenuated.
- chemical , adverse effects : Influenza Vaccines, Vaccines, Attenuated.
- chemical , analysis : Antibodies, Viral.
- immunology : Influenza A virus, Neuraminidase.
- prevention & control : Influenza, Human.
- chemical , therapeutic use : Influenza Vaccines.
- Administration, Intranasal, Adult, Child, Clinical Trials as Topic, Female, Hemagglutination Inhibition Tests, Humans, Male.
Abstract
Live temperature-sensitive influenza virus vaccines were tested in two volunteer experiments. The vaccine virus was originally derived from a temperature-sensitive mutant of influenza A/Great Lakes/1965 (H2N2) produced by chemical mutagenesis with 5-fluorouracil. The ts lesions of this strain were subsequently transferred (HI) antibody. Only 9 men (13%) were infected, presumably as a result of over-attenuation of the virus and/or insufficient titer of the inoculum. In the second experiment (1974), 20 young adults were given 0.5 ml per nostril of vaccine containing a recombinant of influenza A/Udorn/307/72 clone 24 (10(5.5) TCID50/ml) with an in vitro shutoff temperature of 38 degree C. Virus was shed by seven volunteers (maximum titer, 10(2.5)TCID50/ml). None of 21 isolates contained revertant wild type virus. Serum HI and antieuraminidase (NI) and nasal wash neutralizing antibody responses occurred in 11 (55%), 7 (35%), and 8 (40%) volunteers, respectively. Post-vaccination serum HI and NI and nasal neutralizing antibody geometric mean titers were 3.0, 9.4, and 1.7 lob2, respectively. Seven volunteers judged they had colds (symptom scores 4-32). Rhinitis and mild pharyngeal discomfort were the only consistent complaints and fever was absent. The findings in the latter trial will be compared with results of volunteer experiments with Udorn/72 ts-1-(E) in other laboratories and to studies with standard inactivated influenza vaccines given parenterally.
PubMed: 782966
Links to Exploration step
pubmed:782966Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">The use of live attenuated influenza vaccine ts-1(E) in man.</title><author><name sortKey="Gwaltney, J M" sort="Gwaltney, J M" uniqKey="Gwaltney J" first="J M" last="Gwaltney">J M Gwaltney</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="1976">1976</date><idno type="RBID">pubmed:782966</idno><idno type="pmid">782966</idno><idno type="wicri:Area/PubMed/Corpus">000647</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000647</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">The use of live attenuated influenza vaccine ts-1(E) in man.</title><author><name sortKey="Gwaltney, J M" sort="Gwaltney, J M" uniqKey="Gwaltney J" first="J M" last="Gwaltney">J M Gwaltney</name></author></analytic><series><title level="j">Developments in biological standardization</title><idno type="ISSN">0301-5149</idno><imprint><date when="1976" type="published">1976</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Administration, Intranasal</term><term>Adult</term><term>Antibodies, Viral (analysis)</term><term>Child</term><term>Clinical Trials as Topic</term><term>Female</term><term>Hemagglutination Inhibition Tests</term><term>Humans</term><term>Influenza A virus (immunology)</term><term>Influenza Vaccines (administration & dosage)</term><term>Influenza Vaccines (adverse effects)</term><term>Influenza Vaccines (therapeutic use)</term><term>Influenza, Human (prevention & control)</term><term>Male</term><term>Neuraminidase (immunology)</term><term>Vaccines, Attenuated (administration & dosage)</term><term>Vaccines, Attenuated (adverse effects)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Influenza Vaccines</term><term>Vaccines, Attenuated</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Influenza Vaccines</term><term>Vaccines, Attenuated</term></keywords><keywords scheme="MESH" type="chemical" qualifier="analysis" xml:lang="en"><term>Antibodies, Viral</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Influenza A virus</term><term>Neuraminidase</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Influenza, Human</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Influenza Vaccines</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Administration, Intranasal</term><term>Adult</term><term>Child</term><term>Clinical Trials as Topic</term><term>Female</term><term>Hemagglutination Inhibition Tests</term><term>Humans</term><term>Male</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Live temperature-sensitive influenza virus vaccines were tested in two volunteer experiments. The vaccine virus was originally derived from a temperature-sensitive mutant of influenza A/Great Lakes/1965 (H2N2) produced by chemical mutagenesis with 5-fluorouracil. The ts lesions of this strain were subsequently transferred (HI) antibody. Only 9 men (13%) were infected, presumably as a result of over-attenuation of the virus and/or insufficient titer of the inoculum. In the second experiment (1974), 20 young adults were given 0.5 ml per nostril of vaccine containing a recombinant of influenza A/Udorn/307/72 clone 24 (10(5.5) TCID50/ml) with an in vitro shutoff temperature of 38 degree C. Virus was shed by seven volunteers (maximum titer, 10(2.5)TCID50/ml). None of 21 isolates contained revertant wild type virus. Serum HI and antieuraminidase (NI) and nasal wash neutralizing antibody responses occurred in 11 (55%), 7 (35%), and 8 (40%) volunteers, respectively. Post-vaccination serum HI and NI and nasal neutralizing antibody geometric mean titers were 3.0, 9.4, and 1.7 lob2, respectively. Seven volunteers judged they had colds (symptom scores 4-32). Rhinitis and mild pharyngeal discomfort were the only consistent complaints and fever was absent. The findings in the latter trial will be compared with results of volunteer experiments with Udorn/72 ts-1-(E) in other laboratories and to studies with standard inactivated influenza vaccines given parenterally.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">782966</PMID><DateCompleted><Year>1976</Year><Month>11</Month><Day>01</Day></DateCompleted><DateRevised><Year>2007</Year><Month>11</Month><Day>15</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0301-5149</ISSN><JournalIssue CitedMedium="Print"><Volume>33</Volume><PubDate><Year>1976</Year></PubDate></JournalIssue><Title>Developments in biological standardization</Title><ISOAbbreviation>Dev. Biol. Stand.</ISOAbbreviation></Journal><ArticleTitle>The use of live attenuated influenza vaccine ts-1(E) in man.</ArticleTitle><Pagination><MedlinePgn>178-83</MedlinePgn></Pagination><Abstract><AbstractText>Live temperature-sensitive influenza virus vaccines were tested in two volunteer experiments. The vaccine virus was originally derived from a temperature-sensitive mutant of influenza A/Great Lakes/1965 (H2N2) produced by chemical mutagenesis with 5-fluorouracil. The ts lesions of this strain were subsequently transferred (HI) antibody. Only 9 men (13%) were infected, presumably as a result of over-attenuation of the virus and/or insufficient titer of the inoculum. In the second experiment (1974), 20 young adults were given 0.5 ml per nostril of vaccine containing a recombinant of influenza A/Udorn/307/72 clone 24 (10(5.5) TCID50/ml) with an in vitro shutoff temperature of 38 degree C. Virus was shed by seven volunteers (maximum titer, 10(2.5)TCID50/ml). None of 21 isolates contained revertant wild type virus. Serum HI and antieuraminidase (NI) and nasal wash neutralizing antibody responses occurred in 11 (55%), 7 (35%), and 8 (40%) volunteers, respectively. Post-vaccination serum HI and NI and nasal neutralizing antibody geometric mean titers were 3.0, 9.4, and 1.7 lob2, respectively. Seven volunteers judged they had colds (symptom scores 4-32). Rhinitis and mild pharyngeal discomfort were the only consistent complaints and fever was absent. The findings in the latter trial will be compared with results of volunteer experiments with Udorn/72 ts-1-(E) in other laboratories and to studies with standard inactivated influenza vaccines given parenterally.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gwaltney</LastName><ForeName>J M</ForeName><Initials>JM</Initials><Suffix>Jr</Suffix></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Dev Biol Stand</MedlineTA><NlmUniqueID>0427140</NlmUniqueID><ISSNLinking>0301-5149</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007252">Influenza Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014613">Vaccines, Attenuated</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.2.1.18</RegistryNumber><NameOfSubstance UI="D009439">Neuraminidase</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000281" MajorTopicYN="N">Administration, Intranasal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002986" MajorTopicYN="N">Clinical Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006385" MajorTopicYN="N">Hemagglutination Inhibition Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009980" MajorTopicYN="N">Influenza A virus</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007252" MajorTopicYN="N">Influenza Vaccines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007251" MajorTopicYN="N">Influenza, Human</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009439" MajorTopicYN="N">Neuraminidase</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014613" MajorTopicYN="N">Vaccines, Attenuated</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1976</Year><Month>1</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2001</Year><Month>3</Month><Day>28</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1976</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">782966</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/H2N2V1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000647 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 000647 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= H2N2V1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:782966
|texte= The use of live attenuated influenza vaccine ts-1(E) in man.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:782966" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a H2N2V1
| This area was generated with Dilib version V0.6.33. |  |